VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
XLO
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
XLOXilio Therapeutics, Inc.
$7.54$50M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksXLOBalance Sheet

Xilio Therapeutics, Inc. (XLO) Balance Sheet

7Y historyFree accessUpdated daily

Leverage is minimal with total debt of $6.3M and a D/E of 0.09 in 2026Q2, but retained earnings stand at -$434.7M against $72.3M of equity, indicating reliance on capital raised rather than accumulated profits.

Income StatementBalance SheetCash FlowRatios

XLO Balance Sheet

Annual statement

XLO Balance Sheet

Xilio Therapeutics, Inc. (XLO) balance sheet — 7-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19
Total Current Assets126.5M145.03M60.23M48.13M124.5M202.52M20.59M51.1M
Cash & Short-Term Investments122.18M137.53M55.29M44.7M120.39M198.05M19.24M48.84M
Cash Only122.18M137.53M55.29M44.7M120.39M198.05M19.24M48.84M
Short-Term Investments00000000
Accounts Receivable05M000000
Days Sales Outstanding18.2541.7------
Inventory00000000
Days Inventory Outstanding--------
Other Current Assets02.5M4.94M3.42M4.11M4.46M01.01M
Total Non-Current Assets8.33M9.66M10.84M12.8M14.67M19.08M15.73M11.62M
Property, Plant & Equipment6.51M7.85M9.06M11.2M12.84M13.9M14.06M9.87M
Fixed Asset Turnover7.64x5.57x0.70x-----
Goodwill00000000
Intangible Assets00000000
Long-Term Investments1.81M1.81M1.78M01.56M1.55M0194K
Other Non-Current Assets1.82M001.6M267K90K1.66M1.55M
Total Assets134.83M154.69M71.08M60.93M139.16M221.6M36.32M62.72M
Asset Turnover0.36x0.28x0.09x-----
Asset Growth %191.39%117.64%16.66%-56.22%-37.2%510.18%-42.1%-
Total Current Liabilities26.8M56.27M27.26M15.96M21.12M12.78M22.16M5.21M
Accounts Payable753K3.17M2.57M1.05M3.13M3.14M5.44M2.52M
Days Payables Outstanding1.94K750.37---765.551.87K3.83K
Short-Term Debt0003.31M6.67M883K2.33M0
Deferred Revenue (Current)109.58M40.02M13.52M00000
Other Current Liabilities05.73M4.21M4.74M82K3.61M01.92M
Current Ratio4.72x2.58x2.21x3.02x5.89x15.85x0.93x9.81x
Quick Ratio4.72x2.58x2.21x3.02x5.89x15.85x0.93x9.81x
Cash Conversion Cycle-1.92K-------
Total Non-Current Liabilities39.8M63.14M26.22M8.14M12.4M23.39M19.45M19M
Long-Term Debt00003.17M9.63M7.81M9.61M
Capital Lease Obligations14.98M5.61M6.95M8.14M9.19M10.22M11.1M9.02M
Deferred Tax Liabilities000003.54M00
Other Non-Current Liabilities25.38M57.53M0045K0540K374K
Total Liabilities66.6M119.41M53.48M24.1M33.52M36.17M41.6M24.21M
Total Debt5.96M6.95M8.14M12.5M19.94M20.74M21.89M18.63M
Net Debt-116.22M-130.58M-47.15M-32.2M-100.45M-177.32M2.65M-30.21M
Debt / Equity0.09x0.20x0.46x0.34x0.19x0.11x-0.48x
Debt / EBITDA-0.15x-------
Net Debt / EBITDA2.92x-------
Interest Coverage---596.45x---125.33x-91.03x-
Total Equity68.23M35.27M17.6M36.83M105.65M185.43M-5.29M38.51M
Equity Growth %2543.61%100.44%-52.21%-65.14%-43.03%3608.59%-113.72%-
Book Value per Share3.474.224.6018.7553.98463.05-141.261317.21
Total Shareholders' Equity68.23M35.27M17.6M36.83M105.65M185.43M-5.29M38.51M
Common Stock25.38M36.89M5K3K3K3K00
Retained Earnings-440.64M-418.79M-383.75M-325.51M-249.11M-160.89M-85.09M-29.87M
Treasury Stock00000000
Accumulated OCI00000000
Minority Interest00000000

Key Metrics

Growth RegimeMixed
ProfitabilityWeak
Balance SheetAdequate
Cash FlowBurning
Top Statement Risk

Cash runway dependent on financing

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Balance Sheet Rebuilt Through Cash Inflows

Based on reported figures, XLO's total assets rose from $82.6M in 2024Q1 to $154.3M in 2026Q2, with cash climbing to $136.0M, a pattern that points to episodic capital and collaboration inflows rather than self-funded expansion.

The asset build is almost entirely cash, which suggests the balance sheet strengthening reflects financing and milestone receipts rather than improving operating economics. Equity swung negative to -$8.1M in 2025Q3 before recovering to $72.3M, a volatility that warrants investors' attention to the durability of the funding base. The trajectory therefore reads as improving liquidity against a still-unproven earnings base.

Minimal Debt Keeps Leverage Largely Irrelevant

As reported in the balance sheet, XLO's total debt has drifted down from $8.9M to $6.3M over ten quarters, leaving a D/E ratio near 0.09 in 2026Q2 that is low in absolute terms.

Debt is a modest and declining share of the capital structure, so refinancing risk appears limited relative to the cash balance. The more relevant constraint is that total liabilities of $82.0M exceed debt several times over, implying that operating and deferred obligations, not borrowings, drive the liability side. Leverage is therefore not the binding balance sheet concern.

Cash Covers Liabilities With Ample Margin

Based on EDBL-style reporting conventions applied to XLO's figures, the current ratio of 4.25 in 2026Q2 and cash of $136.0M against $82.0M of total liabilities indicate a substantial near-term buffer.

Liquidity appears strong on a point-in-time basis, but the current ratio fell from 3.59 in 2026Q1 and the cash balance dropped from $150.3M over the same quarter, consistent with ongoing consumption. The relevant question is how long this cash lasts given persistent operating losses, and the supplied data does not include a runway estimate. Investors should monitor quarterly burn against the cash balance.

Accumulated Deficit Dwarfs Paid-In Capital

As reported in the balance sheet, retained earnings stood at -$434.7M in 2026Q2 against total equity of $72.3M, showing that the equity base is supported by capital raised rather than accumulated profits.

The persistent deficit, which has deepened every quarter from -$342.7M in 2024Q1, reflects a long history of operating losses funded externally. Equity quality is therefore dependent on continued capital access, and dilution is a plausible consequence of future raises. Investors should treat equity value as contingent on pipeline progress rather than earnings power.

Deferred Revenue May Overstate Cash Stability

Based on reported figures, deferred revenue of $35.3M in 2026Q2 after swinging between $26.5M and $79.0M over the period suggests that a meaningful share of the cash balance may be tied to unearned obligations.

If the $136.0M cash position includes customer prepayments that will be recognized as revenue rather than retained as free cash, the effective liquidity buffer would be smaller than headline cash suggests. The swings in deferred revenue indicate that milestone timing, not steady cash generation, drives the balance. This inference warrants further investigation into the contract terms underlying these balances.

XLO — Frequently Asked Questions

Quick answers to the most common questions about buying XLO stock.

What are the total assets of Xilio Therapeutics, Inc. (XLO)?

As of 2025, Xilio Therapeutics, Inc. (XLO) had total assets of $154.7M including $145.0M in current assets.

How much debt does Xilio Therapeutics, Inc. (XLO) have?

Xilio Therapeutics, Inc. (XLO) carries total debt of $7.0M, offset by $137.5M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Xilio Therapeutics, Inc.?

Xilio Therapeutics, Inc. (XLO) has total shareholders' equity (book value) of $35.3M ($4.22 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Xilio Therapeutics, Inc.'s current ratio and liquidity?

Xilio Therapeutics, Inc. (XLO) reported a current ratio of 2.58x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.